|I. MODIFIED AGREEMENTS|
Change from original
Eli Lilly & Co.
Renewed research collaboration involving an intensive profiling program to define the chemical space that is most suitable for use in discovering lead compounds that are active against important targets
Lilly was given access to selected areas of Cerep's BioPrint database; the renewal of the deal means Lilly will continue to use Cerep's experience in high- hroughput compound profiling to enhance its understanding of the fundamental relationships between chemical structure and biological activity (4/4)**
Extended nonexclusive research license to PER.C6 technology
The agreement allows Novartis to use the technology in manufacturing alphavirus vectors for its vaccine research programs (4/27)
Boehringer Ingelheim GmbH (Germany)
Expanded licensing agreement covering global locations and multiple departments
The agreement covers a suite of software tools and databases for functional data analysis MetaCore, which is used for biomarker discovery, target identification and validation (4/10)
Novogen Ltd. (Australia)
Renegotiated agreement that changes the timing of the payment for an $8M annual milestone for the anticancer drug, phenoxodiol
The payment of future milestone license fees due Dec. 31, and each subsequent year will now begin at the end of the calendar year in which phenoxodiol first receives approval for marketing in the U.S. or any other country (4/4)
Extended the term of the worldwide collaboration to research, develop and commercialize small molecules targeting the vanilloid receptor, VR1
The extension provides Renovis with additional research funding through June 30, 2008, and reflects the goal to advance multiple, small- olecule VR1 antagonists toward the clinic (4/10)
Senomyx Inc. (SNMX)
Ajinomoto Co. Inc. (Japan)
Expanded agreement to include additional territories in the U.S. and Canada
Companies will work to develop and commercialize certain existing flavor ingredients in North America; Senomyx will receive an initial license fee and could receive a milestone payment and royalties (4/26)
|II. TERMINATED AGREEMENTS|
Solvay Pharmaceuticals Inc.
Terminated deal for cetrorelix
AEterna regained rights to the luteinizing hormone-releasing hormone antagonist a year ago in the field of benign prostate hyperplasia; with the terminated deal, it now regains all rights free of charge; Solvay's decision to return the rights were for strategic reasons (5/8)
Procter & Gamble Co.
Terminated deal covering the joint development of pexelizumab in cardiovascular indications
The move followed the Phase III failure of the monoclonal antibody fragment; the deal was first formed in 1999 (4/3)
AstraZeneca plc (UK)
Dropped collaboration on AGI-1067
The atherosclerosis drug missed its primary endpoint in a Phase III trial earlier this year (4/23)
Ortho Biotech Products LP (unit of Johnson & Johnson)
Terminated agreement for Curis' bone morphogenetic protein-7 for kidney disease
The companies did not disclose the reason for the termination; the program is at the preclinical stage (5/21)
Curis Inc. (CRIS)
Procter & Gamble Pharmaceuticals agonist program for hair growth
Terminated September 2005 collaboration on Curis' topically applied Hedgehog
They ended it because compounds did not demonstrate an acceptable safety profile (5/9)
# The information in the chart does not cover agreements between biotech companies or agricultural agreements.
* Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.